Insilico Medicine has just signed a deal worth up to $2.75 billion with Eli Lilly, putting the spotlight firmly on AI-driven drug discovery.
In this episode of Companies to Watch, Dan Koh and Ryan Huang break down what Insilico Medicine actually does, why its Hong Kong IPO drew massive investor demand, and what this latest partnership means for the future of healthcare.

Breakfast Bites: What should you do if you're being gaslighted at work?
05:49

Bigger Pic: Will Regional Flight Cuts Hurt Singapore?
10:23

Mind Your Business: What investors really look for in founders today
13:51